Histone dacetylases (HDACs) are a group of enzymes that remove acetyl groups from
histones and regulate expression of tumor suppressor genes. They are implicated in many …

Inhibitors of histone deacetylases (HDACs) are nowadays part of the therapeutic arsenal
mainly against cancers, with four compounds approved by the Food and Drug …

Histone deacetylase 8 (HDAC8) is a class I histone deacetylase implicated as a therapeutic
target in various diseases, including cancer, X-linked intellectual disability, and parasitic …

Histone deacetylase 8 (HDAC8) is a class I HDAC that catalyzes the deacetylation of histone
and non-histone proteins. As one of the best-characterized isoforms, numerous studies have …

This review classifies drug‐design strategies successfully implemented in the development
of histone deacetylase (HDAC) inhibitors, which have many applications including cancer …

Histone deacetylase (HDAC) inhibitors are proven anticancer therapeutics and have
potential in the treatment of many other diseases including HIV infection, Alzheimer's …

Background: Neglected tropical diseases (NTDs) are closely related to poverty and affect
over a billion people in developing countries. The unmet treatment needs cause high …

Metal-dependent histone deacetylases (HDACs) are key epigenetic regulators that
represent promising therapeutic targets for the treatment of numerous human diseases. Yet …

Histone Deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that
play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis …

Histone deacetylases (HDACs) are enzymes pursued as drug targets in various cancers and
several non-oncological conditions, such as inflammation and neurodegenerative disorders …